Belite Bio submits Japan NDA for tinlarebant under Sakigake
Belite Bio announced submission of a new drug application to Japan’s Ministry of Health, Labour and Welfare for tinlarebant to treat Stargardt disease type 1 under Sakigake designation.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.